Search Within

Nitya Prabhakar Raj

Formats
  1. Meeting Abstract (64)
  2. Journal Article (37)
  3. Guidelines (3)
  4. Editorial (2)
  5. Review (2)
  6. Correspondence (1)
  7. Miscellaneous (1)
Groups
  1. Department of Medicine (110)
  2. Gastrointestinal Oncology Service (110)
  3. Solid Tumor Oncology Division (110)
  4. Weinberg Fellows (110)
  5. Center for Pancreatic Cancer Research (95)
  6. Department of Pathology and Laboratory Medicine (35)

More Groups

People
  1. Diane Reidy (83)
  2. Marinela Capanu (24)
  3. Joanne Chou (22)
  4. Michael Berger (16)
  5. David Klimstra (14)
  6. Tiffany Le (14)

More People

Years
  1. 2025 (5)
  2. 2024 (12)
  3. 2023 (13)
  4. 2022 (17)
  5. 2021 (12)
  6. 2020 (5)

More Years

Publications
  1. Journal of Clinical Oncology (31)
  2. Pancreas (27)
  3. Annals of Oncology (4)
  4. Endocrine-Related Cancer (4)
  5. Journal of Vascular and Interventional Radiology (4)
  6. Laboratory Investigation (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. Lippincott Williams & Wilkins (29)
  3. Oxford University Press (8)
  4. Nature Publishing Group (6)
  5. Bioscientifica Ltd (4)
  6. Elsevier Inc. (4)

More Publishers

Results (110)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized trial evaluating patient experience and preference between octreotide long-acting release and lanreotide for treatment of well-differentiated neuroendocrine tumors
    Journal Article

    Raj, N.; Cruz, E.; O'Shaughnessy, S.; Calderon, C.; Chou, J. F.; Capanu, M.; Heffernan, O.; DeMore, A.; Punn, S.; Le, T.; more...
    JCO Oncology Practice (2022)

    Fulltext@MSK | Save
  • TERT copy number alterations, promoter mutations and rearrangements in adrenocortical carcinomas
    Journal Article

    Gupta, S.; Won, H.; Chadalavada, K.; Nanjangud, G. J.; Chen, Y. B.; Al-Ahmadie, H. A.; Fine, S. W.; Sirintrapun, S. J.; Strong, V. E.; Raj, N.; more...
    Endocrine Pathology (2022)

    Fulltext@MSK | Save
  • Post-embolization global transcription changes in high grade and low grade pancreatic neuroendocrine tumors
    Meeting Abstract

    Clark, M.; Samson, C.; Alexander, E.; Gonzalez, A.; Raj, N.; Reidy-Lagunes, D.; Ziv, E.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104
    Meeting Abstract

    Soares, H. P.; Guthrie, K. A.; Ahmad, S. A.; Washington, M. K.; Ramnaraign, B. H.; Raj, N. P.; Seigel, C.; Bellasea, S.; Chiorean, E. G.; Dasari, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Early-onset well differentiated pancreatic neuroendocrine tumors: Clinical presentation, pathologic features, and oncological outcomes
    Meeting Abstract

    Pulvirenti, A.; Hauser, H.; Le, T.; McIntyre, C. A.; Reidy, D. L.; Wei, A. C. C.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, R. K. G.; Krebs, S.; Reidy, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schoder, H.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab plus chemotherapy)
    Meeting Abstract

    Chan, J. A.; Raj, N. P.; Aggarwal, R. R.; Calabrese, S.; DeMore, A.; Dhawan, M. S.; Fattah, D.; Fong, L.; Grabowsky, J.; Hope, T. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs)
    Meeting Abstract

    Raj, N. P.; Cruz, E.; Chou, J. F.; Capanu, M.; Heffernan, O.; Le, T.; Hauser, H.; Saltz, L. B.; Reidy, D. L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save